Related Experiment Video
Updated: Jan 18, 2026

08:16
Identifying Caspases and their Motifs that Cleave Proteins During Influenza A Virus Infection
Published on: July 21, 2022
1.8K
Machine Learning Integration of Bulk and Single-Cell RNA-Seq Data Reveals Cathepsin B as a Central PANoptosis
Bin Liu1, Lin Zhu1, Caijuan Zhang1
1State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100010, China.
International Journal of Molecular Sciences
|September 13, 2025
Summary
Influenza A virus infection causes excessive PANoptosis, a cell death process leading to lung injury. Researchers identified cathepsin B (CTSB) as a key regulator of this process, suggesting CTSB as a potential therapeutic target.
Area of Science:
- Immunology
- Molecular Biology
- Virology
Background:
- Influenza A virus (IAV) infection causes severe lung injury due to excessive PANoptosis, a programmed cell death pathway.
- The molecular mechanisms driving PANoptosis during IAV infection are not fully understood.
Purpose of the Study:
- To investigate the cellular heterogeneity and transcriptional dynamics of PANoptosis in influenza-infected lungs.
- To identify key molecular regulators of PANoptosis during IAV infection.
Main Methods:
- Integrated bulk and single-cell RNA sequencing (scRNA-seq) data.
- Utilized computational algorithms (AUCell, ssGSEA, AddModuleScore) to quantify PANoptosis activity.
- Employed machine learning (SVM, RF, LASSO) to identify regulatory genes.
- Performed in vivo validation in a mouse model.
Main Results:
- PANoptosis activity was mainly observed in macrophages and neutrophils.
- Cathepsin B (CTSB) was identified as a central regulator of PANoptosis.
- In vivo studies confirmed elevated PANoptosis markers and CTSB expression in IAV-infected mice.
- CTSB may promote NLRP3 inflammasome activation and lysosomal dysfunction-induced cell death.
Conclusions:
- CTSB is a critical mediator linking lysosomal integrity to innate immune-driven lung injury during IAV infection.
- Targeting CTSB may offer a therapeutic strategy to mitigate influenza-associated immunopathology.

